Allogeneic transplantation in older and infirm AML patients, cilta-cel in progressive multiple myeloma, and anti-CD20 therapy in relapsed TTP
Blood Podcast
00:00
ADAM-TS13 Relapses in TTP Patients
96% of patients with an ADAM-TS13 relapse responded to anti-CD20 therapy. Anti-CD20 Therapy proved to be an effective long-term treatment irrespective of relapse pattern. TTP is optimistic that future studies utilizing data from large national databases will provide answers to these questions.
Transcript
Play full episode
